EUCTR2017-004856-41-GB进行中（未招募）1 期
Regeneration in Cervical Degenerative Myelopathy - a multi-centre, double-blind, randomised, placebo controlled trial assessing the efficacy of Ibudilast as an adjuvant treatment to decompressive surgery for degenerative cervical myelopathy - RECEDE Myelopathy
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge0 个研究点目标入组 362 人开始时间: 2020年1月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 362
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, ages 18 to 80 years who have granted informed consent to participate
- •Patients suffering from Degenerative Cervical Myelopathy
- •Have a preoperative mJOA score =8 and =14
- •Scheduled for first surgical decompression as part of usual clinical practice
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 217
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 145
排除标准
- •Previous surgery for DCM
- •DCM symptoms due to cervical trauma (at the discretion of the investigator)
- •Hypersensitivity to Ibudilast or any of the formulation components
- •Evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation including ALP> 1.5x ULN; ALT or AST > 2x ULN; GGT > 3x ULN
- •Evidence of thrombocytopenia at screening through laboratory evaluation including platelet count <5000
- •Active malignancy defined as history of invasive malignancy, except if the patient has received treatment and displayed no clinical signs and symptoms for at least five years
- •Recent history (less than 3 years) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or trial participation
- •Female patients with child bearing potential who are unwilling or unable to use reliable methods of contraception
- •Female patients who are pregnant, lactating or planning pregnancy during the course of the trial.
- •Inability to comply with trial procedures or follow-up schedule including IMP regime
- •Unable to take gelatin based product
- •Participation in another CTIMP or device within the past 30 days from the time of recruitment
- •Functional disability from a concomitant neurological disease that would mask the symptoms of DCM (at the discretion of the investigator). Including but not limited to stroke with residual disability, cerebellar ataxia, Parkinson’s disease, symptomatic lumbar stenosis and multiple sclerosis.
- •Resting pulse < 50 bpm, SA or AV block, uncontrolled hypertension, or QTcF > 450 ms
- •History of stomach or intestinal surgery or any other condition that could interfere with or is judged by the investigator to interfere with absorption, distribution, metabolism, or excretion of IMP
- •Unable to converse, read or write English
研究者
相似试验
招募中
3 期
Regeneration in Cervical Degenerative MyelopathyMyelopathySpinal Cord DiseasesNCT04631471Cambridge University Hospitals NHS Foundation Trust400
进行中（未招募）
3 期
Assessing the efficacy of Ibudilast as an adjuvant treatment to decompressive surgery for degenerative cervical myelopathyISRCTN16682024Cambridge University Hospitals NHS Foundation Trust362
Unknown
不适用
Cerebral Reorganization in Cervical Myelopathy Measured by Navigated Transcranial Magnetic StimulationDegenerative MyelopathyNCT03312608Charite University, Berlin, Germany160
招募中
不适用
A Novel Surgical Criteria for Degenerative Cervical Myelopathy in Chinese EthnicityDegenerative Cervical Spinal StenosisNCT06528730The University of Hong Kong100
招募中
不适用
Fusion or no Fusion After Decompression of the Spinal Cord in Patients With Degenerative Cervical MyelopathyCervical Spondylotic MyelopathyNCT04936074Uppsala University Hospital300